Cognition Therapeutics (CGTX) CFO adds 10,000 shares in open-market buy

Rhea-AI Filing Summary

Cognition Therapeutics Chief Financial Officer John Brendan Doyle bought 10,000 shares of common stock in an open-market purchase at $1.13 per share. The transaction involved directly held shares. Following this purchase, Doyle directly owns a total of 627,509 shares of Cognition Therapeutics common stock.

Insider Trade Summary

Net Buyer: 10,000 shares ($11,300)

Net Buy 1 txn

Insider Doyle John Brendan

Role Chief Financial Officer

Bought 10,000 shs ($11K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$1.13	$11K

Holdings After Transaction: Common Stock — 627,509 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 10,000 shares Purchase price: $1.13 per share Shares owned after transaction: 627,509 shares +1 more

4 metrics

Shares purchased 10,000 shares Open-market purchase of common stock on April 16, 2026

Purchase price $1.13 per share Price paid for Cognition Therapeutics common stock

Shares owned after transaction 627,509 shares Direct holdings of CFO John Brendan Doyle following the purchase

Net share change 10,000 shares Net buy shares for this Form 4 transaction

Key Terms

open-market purchase, Common Stock, Form 4, Chief Financial Officer

4 terms

open-market purchase financial

"described as an open-market purchase at $1.13 per share"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title is reported as Common Stock in the transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"This transaction is disclosed in a Form 4 insider filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Chief Financial Officer financial

"John Brendan Doyle serves as Chief Financial Officer"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle John Brendan

(Last) (First) (Middle)

C/O COGNITION THERAPEUTICS INC

2500 WESTCHESTER AVE.

(Street)

PURCHASE NEW YORK 10577

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COGNITION THERAPEUTICS INC [ CGTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/16/2026		P		10,000	A	$1.13	627,509	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John Brendan Doyle	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cognition Therapeutics (CGTX) report for John Brendan Doyle?

Cognition Therapeutics reported that Chief Financial Officer John Brendan Doyle executed an open-market purchase of 10,000 shares of common stock at $1.13 per share. This transaction is disclosed in a Form 4 insider filing for transparency regarding executive share ownership.

How many Cognition Therapeutics (CGTX) shares did the CFO buy and at what price?

The Chief Financial Officer, John Brendan Doyle, bought 10,000 shares of Cognition Therapeutics common stock at a price of $1.13 per share. The filing classifies this as an open-market purchase of non-derivative common stock under transaction code P.

What are John Brendan Doyle’s Cognition Therapeutics (CGTX) holdings after this Form 4 trade?

After the reported transaction, John Brendan Doyle directly holds 627,509 shares of Cognition Therapeutics common stock. This total reflects his position immediately following the 10,000-share open-market purchase disclosed in the Form 4 filing.

What does transaction code P mean in the Cognition Therapeutics (CGTX) Form 4?

Transaction code P in the Cognition Therapeutics Form 4 indicates a purchase in an open market or private transaction. In this case, it records the CFO’s acquisition of 10,000 common shares at $1.13 per share as a straightforward buy of non-derivative stock.

Was the Cognition Therapeutics (CGTX) insider trade a derivative or common stock transaction?

The insider trade was in Cognition Therapeutics common stock, categorized as a non-derivative security. The Form 4 reports the CFO’s open-market purchase of 10,000 common shares at $1.13 each, with no associated options, warrants, or other derivative instruments in this transaction.